Dec. 2, 2024 Reducing Risk of Opioid Addiction While Continuing to Alleviate Pain By Katz CommunicationsIncreasing the levels of chemicals naturally produced in the body called endocannabinoids may […] Nov. 22, 2024 Major Advances in Treating Lung Blood Clots Could Eliminate Need for ICU Stay, According to New Research at the Lewis Katz School of Medicine at Temple University By Katz CommunicationsA novel “on-the-table” (OTT) therapeutic strategy with a total procedure time of less than one hour […] Oct. 7, 2024 Researchers From Fels Cancer Institute for Personalized Medicine and Fox Chase Cancer Center Reveal Surprising Mechanism for Activating DNA Repair in Cancer By Katz CommunicationsAn enzyme called DNA polymerase theta plays a key role in repairing DNA damage to cancer cells, […] Jun. 12, 2024 New Grant from Alzheimer’s Association Allows Lewis Katz School of Medicine Researchers Opportunity to Identify Rejuvenation Pathways in the Brain, Reversing Cognitive Decline By Katz CommunicationsRecognizing late-life depression as a significant precursor to Alzheimer's disease, primarily due […] Aug. 17, 2023 Novel Treatment Based on Gene Editing Safely and Effectively Removes HIV-Like Virus from Genomes of Non-Human Primates By Katz Communications (Philadelphia, PA) – A single injection of a novel CRISPR gene-editing treatment safely and […] May 3, 2023 Chances of Eliminating HIV Infection Increased by Novel Dual Gene-Editing Approach By Katz CommunicationsGene-editing therapy aimed at two targets – HIV-1, the virus that causes AIDS, and CCR5, the […] Apr. 26, 2023 Existing Drugs Prevent Alzheimer’s Disease-Related Cognitive Impairment in Mice, New Research at The Lewis Katz School of Medicine at Temple University Shows By Katz CommunicationsChanges in blood vessels in the brain linked to the build-up of a sticky protein known as amyloid […] Sep. 21, 2022 First Individual Treated with CRISPR-Based HIV Therapy, a Breakthrough Treatment Pioneered by Researchers at Lewis Katz School of Medicine at Temple University and Developed by Excision BioTherapeutics By Katz CommunicationsIn a major milestone in the search for a cure for HIV/AIDS, a breakthrough gene-editing therapy for […] Jul. 13, 2022 New $4M NIH Grant Awarded to Researchers at Lewis Katz School of Medicine to Fund Groundbreaking Research on Disparities in Hepatitis B and Liver Disease in Asian-Americans By Katz CommunicationsAmong the 2.4 million Americans living with chronic hepatitis B virus (HBV), Asian-Americans are […] Feb. 24, 2022 First Clinical Trial of CRISPR-Based HIV Therapy Founded on Breakthrough Research at Lewis Katz School of Medicine By Katz CommunicationsThe first clinical trial of a gene-editing therapy for human immunodeficiency virus type 1 (HIV) […] Sep. 15, 2021 Groundbreaking Research at Temple Paves Way for First Trial of CRISPR-Based HIV Therapy in Human Patients By Katz Communications For the last seven years, researchers at the Lewis Katz School of Medicine at Temple University […] Aug. 28, 2021 Faculty Spotlight: Beata Kosmider, PhD By Katz CommunicationsBeata Kosmider, PhD, Associate Professor of Microbiology, Immunology, and Inflammation at the Lewis […] Aug. 13, 2021 Fels and Fox Chase Researchers Highlight Roles of TET2 and DNMT3A Mutations in Personalized Medicine-Guided Synthetic Lethality Against Leukemia By Katz CommunicationsIn a recent study published in Cancer Research, researchers from Fels Cancer Institute for […] May 24, 2021 Lewis Katz School of Medicine’s Center for Urban Bioethics Receives $1 Million Legacy Bequest and $50,000 Donation from Dr. Margaret Barnes By Katz CommunicationsBy the time Margaret M. Barnes arrived at Temple University’s medical school in 1977, she had […] Feb. 18, 2021 Excision BioTherapeutics Secures $60 Million to Advance CRISPR-Based Gene Editing Constructs Developed at Temple into Clinical Trial for People Living with Chronic HIV Infection By Katz Communications Excision BioTherapeutics, Inc. (Excision) has secured $60 million in investor financing to advance […] Load More
Dec. 2, 2024 Reducing Risk of Opioid Addiction While Continuing to Alleviate Pain By Katz CommunicationsIncreasing the levels of chemicals naturally produced in the body called endocannabinoids may […] Nov. 22, 2024 Major Advances in Treating Lung Blood Clots Could Eliminate Need for ICU Stay, According to New Research at the Lewis Katz School of Medicine at Temple University By Katz CommunicationsA novel “on-the-table” (OTT) therapeutic strategy with a total procedure time of less than one hour […] Oct. 7, 2024 Researchers From Fels Cancer Institute for Personalized Medicine and Fox Chase Cancer Center Reveal Surprising Mechanism for Activating DNA Repair in Cancer By Katz CommunicationsAn enzyme called DNA polymerase theta plays a key role in repairing DNA damage to cancer cells, […] Jun. 12, 2024 New Grant from Alzheimer’s Association Allows Lewis Katz School of Medicine Researchers Opportunity to Identify Rejuvenation Pathways in the Brain, Reversing Cognitive Decline By Katz CommunicationsRecognizing late-life depression as a significant precursor to Alzheimer's disease, primarily due […] Aug. 17, 2023 Novel Treatment Based on Gene Editing Safely and Effectively Removes HIV-Like Virus from Genomes of Non-Human Primates By Katz Communications (Philadelphia, PA) – A single injection of a novel CRISPR gene-editing treatment safely and […] May 3, 2023 Chances of Eliminating HIV Infection Increased by Novel Dual Gene-Editing Approach By Katz CommunicationsGene-editing therapy aimed at two targets – HIV-1, the virus that causes AIDS, and CCR5, the […] Apr. 26, 2023 Existing Drugs Prevent Alzheimer’s Disease-Related Cognitive Impairment in Mice, New Research at The Lewis Katz School of Medicine at Temple University Shows By Katz CommunicationsChanges in blood vessels in the brain linked to the build-up of a sticky protein known as amyloid […] Sep. 21, 2022 First Individual Treated with CRISPR-Based HIV Therapy, a Breakthrough Treatment Pioneered by Researchers at Lewis Katz School of Medicine at Temple University and Developed by Excision BioTherapeutics By Katz CommunicationsIn a major milestone in the search for a cure for HIV/AIDS, a breakthrough gene-editing therapy for […] Jul. 13, 2022 New $4M NIH Grant Awarded to Researchers at Lewis Katz School of Medicine to Fund Groundbreaking Research on Disparities in Hepatitis B and Liver Disease in Asian-Americans By Katz CommunicationsAmong the 2.4 million Americans living with chronic hepatitis B virus (HBV), Asian-Americans are […] Feb. 24, 2022 First Clinical Trial of CRISPR-Based HIV Therapy Founded on Breakthrough Research at Lewis Katz School of Medicine By Katz CommunicationsThe first clinical trial of a gene-editing therapy for human immunodeficiency virus type 1 (HIV) […] Sep. 15, 2021 Groundbreaking Research at Temple Paves Way for First Trial of CRISPR-Based HIV Therapy in Human Patients By Katz Communications For the last seven years, researchers at the Lewis Katz School of Medicine at Temple University […] Aug. 28, 2021 Faculty Spotlight: Beata Kosmider, PhD By Katz CommunicationsBeata Kosmider, PhD, Associate Professor of Microbiology, Immunology, and Inflammation at the Lewis […] Aug. 13, 2021 Fels and Fox Chase Researchers Highlight Roles of TET2 and DNMT3A Mutations in Personalized Medicine-Guided Synthetic Lethality Against Leukemia By Katz CommunicationsIn a recent study published in Cancer Research, researchers from Fels Cancer Institute for […] May 24, 2021 Lewis Katz School of Medicine’s Center for Urban Bioethics Receives $1 Million Legacy Bequest and $50,000 Donation from Dr. Margaret Barnes By Katz CommunicationsBy the time Margaret M. Barnes arrived at Temple University’s medical school in 1977, she had […] Feb. 18, 2021 Excision BioTherapeutics Secures $60 Million to Advance CRISPR-Based Gene Editing Constructs Developed at Temple into Clinical Trial for People Living with Chronic HIV Infection By Katz Communications Excision BioTherapeutics, Inc. (Excision) has secured $60 million in investor financing to advance […]
